Publications

461 publications

Enter search criteria

Keyword

Fill in keyword(s) to narrow your search.

Period

Last 7 days Last 30 days Last 365 days Specific period

Period from

The start date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

Period up to

The end date was not recognised. Please enter the date in the following format: DD-MM-YYYY.

The end date may not occur before the start date.

Type

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:

Date
Relevance

GVS advice on volanesorsen (Waylivra)

The National Health Care Institute advises the Minister to include volanesorsen on List 1B of the GVS. Volanesorsen (Waylivra®) ...

Report | 10-01-2022
GVS advice Tezacaftor/ivacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) extension of further conditions

The National Health Care Institute completed its assessment whether the further conditions of tezacaftor/ivacaftor (Symkevi®) and ...

Report | 21-12-2021
Package advice on ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®) for the treatment of inoperable malign pleural mesothelioma

The National Health Care Insititute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...

Report | 17-12-2021
Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS

The National Health Care Institute has completed its assessment whether ravulizumab (Ultomiris®) can be included in the insured ...

Report | 15-12-2021
GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis

The National Health Care Institute recommends the Minister to include tirbanibulin on List 1A in cluster 0D06BBADC V of the GVS. ...

Report | 01-12-2021
GVS advice fostemsavir (Rukobia®) for the treatment of adults with multidrug resistant HIV-1 infection

The National Health Care Institute recommends the Minister to include fostemsavir (Rukobia®) in the GVS on List 1B and List 2 of ...

Report | 01-12-2021
Package advice for the lock procedure drug osimertinib (Tagrisso®)

The National Health Care Institute has completed its assessment whether osimertinib (Tagrisso®) can be included in the insured ...

Report | 15-11-2021
Package advice venetoclax (Venclyxto®)

The National Health Care Institute has completed its assessment whether venetoclax (Venclyxto®) can be included in the insured ...

Report | 10-11-2021
GVS advice on levodopa/carbidopa/entacapon intestinal gel (Lecigon®) for the treatment of Parkinson's disease

The National Health Care Institute advises the Minister to include Lecigon® intestinal gel in the GVS only if a price adjustment ...

Report | 02-11-2021
GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)

National Health Care Institute has completed its assessment whether ponesimod (Ponvory®) can be included in the ...

Report | 26-10-2021

Publications

461 publications

GVS advice on volanesorsen (Waylivra)

GVS advice Tezacaftor/ivacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) extension of further conditions

Package advice on ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®) for the treatment of inoperable malign pleural mesothelioma

Package advice ravulizumab (Ultomiris®) for the treatment of PNH and aHUS

GVS advice tirbanibulin (Klisyri®) for the treatment of adults with actinic keratosis

GVS advice fostemsavir (Rukobia®) for the treatment of adults with multidrug resistant HIV-1 infection

Package advice for the lock procedure drug osimertinib (Tagrisso®)

Package advice venetoclax (Venclyxto®)

GVS advice on levodopa/carbidopa/entacapon intestinal gel (Lecigon®) for the treatment of Parkinson's disease

GVS assessment ponesimod (Ponvory®) for the treatment of relapsing forms of multiple sclerosis (RMS)

Go to